Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDS-1001 in Relapsed/Refractory Acute Myeloid Leukemia
NCT04220684Phase 1Completed
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of mbIL21-expanded natural killer cells in acute myeloid leukemia (AML) (2 arms). Primary endpoints: Maximum Tolerated Dose at 63 days and Incidence of Adverse Events at 28 days. Started Jun 2020; status: completed.
02
Drugs
mbIL21-expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04220684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220684.